0000899243-22-028246.txt : 20220810 0000899243-22-028246.hdr.sgml : 20220810 20220810160606 ACCESSION NUMBER: 0000899243-22-028246 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220808 FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALTSHULER DAVID CENTRAL INDEX KEY: 0001550395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 221151814 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-08 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001550395 ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Global Research and CSO Common Stock 2022-08-08 4 M 0 1304 187.53 A 37381 D Common Stock 2022-08-08 4 S 0 222 290.32 D 37159 D Common Stock 2022-08-08 4 S 0 424 291.53 D 36735 D Common Stock 2022-08-08 4 S 0 210 293.02 D 36525 D Common Stock 2022-08-08 4 S 0 302 293.99 D 36223 D Common Stock 2022-08-08 4 S 0 146 295.14 D 36077 D Stock Option (Right to Buy) 187.53 2022-08-08 4 M 0 1304 0.00 D 2029-02-05 Common Stock 1304 2607 D Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $290.32 (range $290.05 to $290.64). Open market sales reported on this line occurred at a weighted average price of $291.53 (range $291.06 to $291.91). Open market sales reported on this line occurred at a weighted average price of $293.02 (range $292.41 to $293.36). Open market sales reported on this line occurred at a weighted average price of $293.99 (range $293.58 to $294.26). Open market sales reported on this line occurred at a weighted average price of $295.14 (range $294.74 to $295.53). The option vests in 16 quarterly installments from 2/6/2019. /s/ Joy Liu, Attorney-in-Fact 2022-08-10